Attending European Renal Association (ERA)’s Congress this May? We’ll be sharing oral presentations with data on our investigational agent felzartamab including interim results from the Phase 2 IGNAZ study results in IgA nephropathy (IgAN) and Phase 2 investigator-sponsored study results in antibody-mediated rejection (AMR) in kidney transplant recipients. See the more details about our abstracts here: https://lnkd.in/e9V85DFB
